For the quarter ending 2025-09-30, GTBP had -$2,700K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,114 | -2,209 |
| Unrealized gain on short-term investments | - | 0 |
| Stock based compensation | 379 | 7 |
| Issuance of warrants for vrt waiver | 0 | 44 |
| Change in fair value of warrant liability | -232 | -12 |
| (increase) in operating lease right-of-use assets | - | 0 |
| Gain on settlement of debt | 0 | 998 |
| Gain on extinguishment of debt | 0 | 200 |
| (increase) decrease in prepaid expenses | -103 | 225 |
| Decrease in accounts payable and accrued expenses | -813 | -1,623 |
| Net cash used in operating activities | -3,677 | -5,216 |
| Sale of investments | - | 0 |
| Net cash provided by investing activities | - | 0 |
| Exercise of warrants and issuance of inducement warrants for cash, net | 0 | 1,052 |
| Proceeds from issuance of series l convertible preferred stock and warrants, net | 1,062 | 5,441 |
| Payment of dividend on series l convertible preferred stock | 85 | - |
| Net cash provided by financing activities | 977 | 6,493 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -2,700 | 1,277 |
| Cash and cash equivalents at beginning of period | 4,044 | - |
| Cash and cash equivalents at end of period | 2,621 | - |
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)